Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline

Shieh Yueh Yang*, Huei Chun Liu, Wen Ping Chen

*Corresponding author for this work

Research output: Contribution to journalReview articlepeer-review

5 Citations (Scopus)

Abstract

Although the concentrations of Alzheimer’s disease (AD) biomarkers Aβ1–40, Aβ1–42 and tau protein are very low in human plasma, ultrasensitive assays such as immunomagnetic reduction (IMR) are able to precisely quantify them. Review articles have described the detailed working mechanism of IMR and revealed the feasibility of detecting early-stage AD by assaying these plasma biomarkers with IMR. In this review, we aimed to compare the significance of these plasma biomarkers in predicting cognitive decline in patients with Down syndrome, stroke, or amnestic mild cognitive impairment based on findings in the literature. We found that plasma Aβ1–42 might play the predominant role in predicting cognitive decline in these patients.

Original languageEnglish
Pages (from-to)435-442
Number of pages8
JournalNeurology and Therapy
Volume9
Issue number2
DOIs
Publication statusPublished - 2020 Dec 1
Externally publishedYes

Keywords

  • Cognitive decline
  • Down syndrome
  • Immunomagnetic reduction
  • Plasma biomarkers
  • Stroke

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology

Fingerprint

Dive into the research topics of 'Immunomagnetic Reduction Detects Plasma Aβ1–42 Levels as a Potential Dominant Indicator Predicting Cognitive Decline'. Together they form a unique fingerprint.

Cite this